Key Takeaways:
10x Genomics (NASDAQ: TXG) reported a first-quarter loss per share of 10 cents, significantly narrower than analyst expectations, as strong growth in its consumables business and disciplined cost controls offset weaker instrument sales.
The company’s performance, detailed in its May 8 report, showed continued demand for its single-cell analysis products even as research customers remain cautious on capital expenditures. Revenue of $150.8 million beat consensus estimates, though it marked a slight decline from the prior-year quarter which included a significant one-time license payment. Excluding that payment, revenue grew 9 percent.
The results underscore a key shift in the company's financial profile, with gross margins expanding 220 basis points to 70.3 percent and operating losses narrowing to $17 million from $39.3 million a year earlier. 10x Genomics maintained its full-year revenue guidance of $600 million to $625 million, signaling management’s confidence in its outlook despite a challenging macroeconomic environment for the life sciences sector.
The core of 10x Genomics' strong quarter was its consumables segment, which saw revenue climb 12.5% year-over-year to $129.8 million. This growth indicates robust utilization of the company's installed base of instruments by its research and clinical customers. The performance of the consumables business was critical in offsetting a 23.9% year-over-year decline in instrument revenue, which totaled $11.3 million, reflecting continued budget constraints on high-value capital equipment in the academic and biotech sectors. This headwind is also being navigated by peers like Pacific Biosciences (PACB), which noted a muted academic funding environment.
Geographically, the company saw strength outside of its primary market. Revenue from Europe, the Middle East, and Africa (EMEA) grew 15.5% to $36.9 million, while Asia-Pacific revenue increased 4.4% to $33.9 million. These gains were offset by an 11.6% decline in the Americas, its largest region.
With 2026 guidance reaffirmed, investor focus now shifts to the company's next major catalyst: the commercial launch of its Atera spatial whole-transcriptome platform in the second half of the year. Unveiled in April 2026, Atera is designed to provide single-cell sensitivity at a large scale, a significant technological step forward. The company has already secured early adoption commitments from major research consortia and AI-focused partners.
The performance of 10x Genomics' stock, which has gained 32.8% year-to-date, reflects investor optimism about the company's strategic direction and cost management. The successful launch and adoption of the Atera platform will be critical for sustaining this momentum and proving that the company can offset broader capital spending pressures through innovation.
This article is for informational purposes only and does not constitute investment advice.
